(+)-YK-4-279
货号：
11167-25mg 基本售价：
14700.0 元 规格：
25 mg
产品信息
概述| 货号 | 11167-25mg |
| 描述 | Ewing’s sarcoma is characterized by the formation of an oncogenic fusion protein, EWS-FLI1, which binds to RNA helicase central to disease. YK-4-279 binds to EWS-FLI1 (Kd = 9.48 μM), blocking the interaction of EWS-FLI1 and RNA helicase and driving apoptosis in Ewing’s sarcoma family tumors.1 Through these effects, YK-4-279 reduces the growth of Ewing’s sarcoma orthotopic xenografts. Importantly, it is effective in Ewing’s sarcoma cells, both in vitroandin vivo, that are chemotherapy-resistant.2 YK-4-279 also binds the ETS transcription factors ERG and ETV1 (Kd = 11.7 and 17.4, respectively), which form fusion proteins that contribute to some types of prostate cancer.3 (+)-YK-4-279 is a highly purified enantiomer of YK-4-279. Its properties have not been characterized. |
性能| 供应商 | Cayman |
| 应用文献 |
1.Erkizan, H.V.,Kong, Y.,Merchant, M., et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nature Medicine 15(7), 750-756 (2009).
2.Awad, O.,Yustein, J.T.,Shah, P., et al. High ALDH activity identifies chemotherapy-resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 5(11), 1-17 (2010).
3.Rahim, S.,Beauchamp, E.M.,Kong, Y., et al. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One 6(4), 1-8 (2011).
|
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 366.2 |
| 分子式 | C17H13Cl2NO4 |
| CAS号 | 1261038-93-0 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
